Low-density lipoprotein-dependent and independent effects of statins on prevention of major coronary events: Meta-regression of randomized placebo-controlled trials

International Journal of Cardiology

Volumn 168, Issue 5, 2013, Pages 4850-4853

  Takagi, Hisato ^a   Umemoto, Takuya ^a  

^a SHIZUOKA MEDICAL CENTER   (Japan)

Author keywords

Atorvastatin; Coronary disease; Low density lipoprotein; Meta regression; Randomized controlled trial; Statin

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CORONARY ARTERY DISEASE; DRUG DOSE TITRATION; DRUG EFFECT; HUMAN; LETTER; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; SYSTEMATIC REVIEW; CONTROLLED CLINICAL TRIAL (TOPIC); CORONARY DISEASE; DYSLIPIDEMIAS; PROCEDURES;

CONTROLLED CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRIMARY PREVENTION; SECONDARY PREVENTION;

EID: 84886425164     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.07.067     Document Type: Article

References (64)

1. H. Naci, J.J. Brugts, R. Fleurence, B. Tsoi, H. Toor, and A. Ades Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials Eur J Prev Cardiol 20 2013 641 657
2. J.R. Kizer, C. Madias, and B. Wilner Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy Am J Cardiol 105 2010 1289 1296
3. The Pravastatin Multinational Study Group for Cardiac Risk Patients Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors Am J Cardiol 72 1993 1031 1037
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
5. GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico) Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? Ital Heart J 1 2000 810 820
6. B.D. Behounek, M.E. McGovern, K.B. Kassler-Taub, J.S. Markowitz, and M. Bergman A multinational study of the effects of low-dose pravastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia. Pravastatin Multinational Study Group for Diabetes Clin Cardiol 17 1994 558 562
7. M.E. Bertrand, E.P. McFadden, and J.C. Fruchart Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty J Am Coll Cardiol 30 1997 863 869
8. C.D. Furberg, B. Pitt, R.P. Byington, J.S. Park, and M.E. McGovern Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries Am J Cardiol 76 1995 60C 63C
9. J.W. Jukema, A.V. Bruschke, and A.J. van Boven Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS) Circulation 91 1995 2528 2540
10. M. Mercuri, M.G. Bond, and C.R. Sirtori Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study Am J Med 101 1996 627 634
11. C.D. Furberg, B. Pitt, R.P. Byington, J.S. Park, and M.E. McGovern Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries Am J Cardiol 76 1995 60C 63C
12. F.M. Sacks, M.A. Pfeffer, and L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009
13. R. Salonen, K. Nyyssönen, and E. Porkkala Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries Circulation 92 1995 1758 1764
14. J. Shepherd, S.M. Cobbe, and I. Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 333 1995 1301 1307
15. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) JAMA 288 2002 2998 3007
16. Y. Sawayama, C. Shimizu, and N. Maeda Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST) J Am Coll Cardiol 39 2002 610 616
17. J. Shepherd, G.J. Blauw, and M.B. Murphy Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630
18. J.H. Lewis, M.E. Mortensen, S. Zweig, M.J. Fusco, J.R. Medoff, R. Belder, and Pravastatin in Chronic Liver Disease Study Investigators Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial Hepatology 46 2007 1453 1463
19. H. Makuuchi, A. Furuse, and M. Endo Effect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgery Circ J 69 2005 636 643
20. T. Nakagawa, T. Kobayashi, and N. Awata Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) study Int J Cardiol 97 2004 107 114
21. H. Nakamura, K. Arakawa, and H. Itakura Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial Lancet 368 2006 1155 1163
22. H. Yokoi, M. Nobuyoshi, K. Mitsudo, A. Kawaguchi, A. Yamamoto, and ATHEROMA Study Investigators Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study Circ J 69 2005 875 883
23. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
24. MAAS Investigators Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) Lancet 344 1994 633 638
25. H.P. Bestehorn, U.F. Rensing, and H. Roskamm The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS) Eur Heart J 18 1997 226 234
26. K.K. Teo, J.R. Burton, and C.E. Buller Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) Circulation 102 2000 1748 1754
27. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
28. V.G. Athyros, A.A. Papageorgiou, and B.R. Mercouris Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study Curr Med Res Opin 18 2002 220 228
29. H.M. Colhoun, D.J. Betteridge, and P.N. Durrington Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
30. E.R. Mohler III, W.R. Hiatt, and M.A. Creager Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease Circulation 108 2003 1481 1486
31. P. Amarenco, J. Bogousslavsky, and A. Callahan III High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 2006 549 559
32. J.H. Bae, E. Bassenge, K.Y. Kim, Y.C. Synn, K.R. Park, and M. Schwemmer Effects of low-dose atorvastatin on vascular responses in patients undergoing percutaneous coronary intervention with stenting J Cardiovasc Pharmacol Ther 9 2004 185 192
33. A.E. Durazzo, F.S. Machado, and D.T. Ikeoka Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial J Vasc Surg 39 2004 967 975 [discussion 975-6]
34. R.H. Knopp, M. d'Emden, J.G. Smilde, and S.J. Pocock Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN) Diabetes Care 29 2006 1478 1485
35. M.J. Koren, D.B. Hunninghake, and ALLIANCE Investigators Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study J Am Coll Cardiol 44 2004 1772 1779
36. P.S. Sever, B. Dahlöf, and N.R. Poulter Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158
37. P.H. Stone, D.M. Lloyd-Jones, and S. Kinlay Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of Myocardial Ischemia Study Circulation 111 2005 1747 1755
38. D.H. Blankenhorn, S.P. Azen, and D.M. Kramsch Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS) Ann Intern Med 119 1993 969 976
39. R.H. Bradford, C.L. Shear, and A.N. Chremos Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up Am J Cardiol 74 1994 667 673
40. J.R. Downs, M. Clearfield, and S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
41. C.D. Furberg, H.P. Adams Jr., and W.B. Applegate Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group Circulation 90 1994 1679 1687
42. A. Kleemann, S. Eckert, and A. von Eckardstein Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT) Eur Heart J 20 1999 1393 1406
43. D. Waters, L. Higginson, and P. Gladstone Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial Circulation 89 1994 959 968
44. W.S. Weintraub, S.J. Boccuzzi, and J.L. Klein Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group N Engl J Med 331 1994 1331 1337
45. J.R. Crouse III, J.S. Raichlen, and W.A. Riley Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial JAMA 297 2007 1344 1353
46. Gissi-HF Investigators, L. Tavazzi, and A.P. Maggioni Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial Lancet 372 2008 1231 1239
47. J. Kjekshus, E. Apetrei, and V. Barrios Rosuvastatin in older patients with systolic heart failure N Engl J Med 357 2007 2248 2261
48. P.M. Ridker, E. Danielson, and F.A. Fonseca Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
49. B. Jacotot, J.D. Banga, P. Pfister, and M. Mehra Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. The French-Dutch Fluvastatin Study Group Br J Clin Pharmacol 38 1994 257 263
50. G. Riegger, C. Abletshauser, and M. Ludwig The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment Atherosclerosis 144 1999 263 270
51. P.W. Serruys, D.P. Foley, and G. Jackson A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial Eur Heart J 20 1999 58 69
52. P.W. Serruys, P. de Feyter, and C. Macaya Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial JAMA 287 2002 3215 3222
53. R. Sahni, A.R. Maniet, G. Voci, and V.S. Banka Prevention of restenosis by lovastatin after successful coronary angioplasty Am Heart J 121 1991 1600 1608
54. J.J. Deeks, J.P. Higgins, D.G. Altman Chapter 9: analysing data and undertaking meta-analyses J.P. Higgins, and S. Green Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011 [Available from www.cochrane-handbook.org ]
55. P.J. Delahoy, D.J. Magliano, K. Webb, M. Grobler, and D. Liew The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis Clin Ther 31 2009 236 244
56. Cholesterol Treatment Trialists' (CTT) Collaborators, B. Mihaylova, and J. Emberson The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
57. H. Takagi, and T. Umemoto A meta-analysis of randomized trials for effects of atorvastatin on renal function in chronic kidney disease Int J Cardiol 152 2011 242 244
58. H. Takagi, and T. Umemoto A meta-analysis of randomized trials for effects of periprocedural atorvastatin on contrast-induced nephropathy Int J Cardiol 153 2011 323 325
59. H. Takagi, and T. Umemoto Atorvastatin, not rosuvastatin, improves cardiac function in heart failure: a meta-analysis of randomized trials Int J Cardiol 155 2012 296 299
60. H. Takagi, and T. Umemoto Atorvastatin decreases lipoprotein(a): a meta-analysis of randomized trials Int J Cardiol 154 2012 183 186
61. H. Takagi, and T. Umemoto Atorvastatin reduces coronary plaque volume in dependence on reductions in low-density lipoprotein: a meta-analysis and meta-regression of randomized controlled trials Int J Cardiol 157 2012 114 116
62. H. Takagi, and T. Umemoto Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials Int J Cardiol 157 2012 255 257
63. H. Takagi, H. Yamamoto, K. Iwata, S.N. Goto, and T. Umemoto Effects of atorvastatin on carotid intima media thickness: a meta-analysis of randomized controlled trials Int J Cardiol 159 2012 69 72
64. H. Takagi, H. Yamamoto, K. Iwata, S.N. Goto, and T. Umemoto Low-density lipoprotein-independent improvement of flow-mediated dilatation with atorvastatin: a meta-analysis and meta-regression of randomized controlled trials Int J Cardiol 158 2012 285 289